Clinical Trial Update: Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for lenalidomide and AT-101 in relapsed B-cell chronic lymphocytic leukemia (Phase 1/2) has terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• AT-101 (gossypol acetic acid)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-06-16